VolitionRx Limited Announces Pricing Of Underwritten Public Offering Of 11.55M Shares Of Common Stock And Accompanying Warrants At $0.52 Per Unit

Author: Benzinga Newsdesk | October 10, 2025 08:35am

VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 11,550,000 shares of its common stock and warrants to purchase up to 11,550,000 shares of its common stock. The public offering price of for each share of common stock and an accompanying warrant to purchase one share of common stock is $0.52 per set of securities (with $0.01 allocated to the warrant). Each warrant has an exercise price per share of $0.60, is exercisable immediately upon issuance, and expires five years from the issuance date.

In connection with the offering, Volition has granted the underwriter a 30-day option to purchase up to an additional 1,732,500 shares of its common stock together with warrants to purchase up to 1,732,500 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the offering.

Assuming no exercise of the underwriter's option, the aggregate gross proceeds to Volition from the offering, before deducting underwriting commissions and other estimated offering expenses payable by Volition, and excluding the exercise of any warrants, are expected to be approximately $6.0 million. The additional gross proceeds to the Company from the exercise of the warrants, if fully-exercised and assuming no exercise of the underwriter's option, will be approximately $6.9 million. However, no assurance can be given that any of these warrants will be exercised.

All of the securities in the offering are being offered by Volition. The offering is expected to close on or about October 14, 2025, subject to the satisfaction of customary closing conditions.

Posted In: VNRX